• # LGM Pharma is a Palbociclib CAS# 571190-30-2 API supplier distributor based in the USA. Inquire about DMF, cGMP, price, availability, samples, sourcing, purity and more.
  • # Questions? Call our customer API support number 1-(800)-881-8210.
  • # LGM Pharma offers this active ingredient but not the finished dosage forms.
  • Inquire about this product >>

Product Details:

  • Product Name: Palbociclib
  • CAS #: 571190-30-2
  • Mode of Action:

    Palbociclib works as a highly potent and selective inhibitor of CDK4 and -6 in patients with advanced estrogen receptor positive, HER-2 negative breast cancer. When used in conjunction with anticancer therapy Letrozole, Palbociclib has proven to significantly promote progression-free survival in patients. Studies have determined that In vitro, Palbociclib reduced cellular proliferation of ER-positive breast cancer cells by effectively blocking the progression of the cell from the G1 into S phase of the cell cycle.

  • Pharmacodynamics:

    Regarding Cardiac Electrophysiology Palbociclib elicited no substantial change in the QTc interval in studies of patients diagnosed with metastatic estrogen receptor positive, HER-2 negative breast cancer. The binding of Palbociclib to plasma proteins in vitro was valued at 85 percent, with no concentration dependence over the expected range of 500 ng/mL to 5000 ng/mL.

  • Metabolism:

    Palbociclib is metabolized both in vitro and in vivo via hepatic metabolism in humans. Post oral administration of a one-time dose of 125 milligrams of Palbociclib the primary metabolic pathways have been observed to involve both oxidation and sulfonation, along with with glucuronidation and acylation as contributing minor pathways.

  • Toxicity:

    The toxicity of Palbociclib alongside Letrozole was found to be acceptable in extensive and comprehensive studies. Adverse events noted included anemia, neutropenia and fatigue.

  • IUPAC: 6-acetyl-8-cyclopentyl-5-methyl-2-[(5-piperazin-1-ylpyridin-2-yl)amino]pyrido[2, 3-d]pyrimidin-7(8H)-one
  • PubChem: 5330286
  • Formula: C24H29N7O2
  • Molecular Mass: 447.5328
  • Synonyms: 6-acetyl-8-cyclopentyl-5-methyl-2-(5-piperazin-1-ylpyridin-2-ylamino)-8H-pyrido(2,3-d)pyrimidin-7-one; OTAVA-BB 1115529; PD-0332991; Palbociclib
  • InChl: InChI=1/C24H29N7O2/c1-15-19-14-27-24(28-20-8-7-18(13-26-20)30-11-9-25-10-12-30)29-22(19)31(17-5-3-4-6-17)23(33)21(15)16(2)32/h7-8,13-14,17,25H,3-6,9-12H2,1-2H3,(H,26,27,28,29)
  • General Reference:

    Weinberg RA. The Biology of Cancer. 2nd ed. New York: Garland Science; 2014.https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4128689/

Products currently covered by valid US Patents are offered for R&D use in accordance with 35 USC 271(e)+A13(1). Any patent infringement and resulting liability is solely at buyer risk.

API’s From Quality Manufacturers:

  • Streamlined API supply towards initial research stages as well as larger quantities of cGMP material for clinical trials and product commercialization
  • Premium quality GMP certified and fully accredited API manufacturing plants

 

  • Technical packages as well as access to filed DMF,
    ASMF or CEP (subject to availability)
  • Regulatory and technical assistance towards any
    submission type based on specific customer requirements

LGM Pharma Acquires CDMO

On July 27, 2020, LGM Pharma announced its acquisition of the formulation development and drug product contract manufacturing business of Nexgen Pharma, Inc. As a result, you will notice our new logo and visuals throughout the website. We’re working on updates to reflect the exciting, expanded CDMO capabilities and services we now can offer you.

This website uses cookies. By using our site, you agree to our terms of service